iNCOVACC and Nasal Vaccine Platforms

Introduction And Mechanism Of Action

iNCOVACC (BBV154) is India's indigenous intranasal COVID-19 vaccine, co-developed by Bharat Biotech and Washington University.
Approved by the Drug Controller General of India (DCGI) in 2022 as the world's first nasal COVID-19 vaccine for primary 2-dose (days 0 and 28) and heterologous booster regimens in adults.
Utilizes a replication-deficient chimpanzee adenovirus (ChAd) vector expressing the SARS-CoV-2 spike protein.
Delivers antigens directly to the nasal mucosa, eliciting robust mucosal IgA, systemic neutralizing IgG, and T-cell responses.
An updated formulation, iNCOVACC 2.0 (launched May 2026), incorporates updated spike proteins targeting emerging variants like JN.1.

Traditional intramuscular (IM) vaccines induce systemic immunity but provide weak mucosal protection at the nasopharynx, which is the primary site of viral entry.
Nasal vaccines stimulate secretory IgA (sIgA) and tissue-resident memory T-cells, enhancing local mucosal defense and potentially reducing long-COVID sequelae.
Real-world modeling suggests nasal delivery platforms can reduce pediatric viral transmission by 40% to 60% compared to IM routes.
Needle-free, painless nasal drop administration eliminates injection phobia, significantly improving compliance and reducing dropout rates in young children.
Excellent cold-chain stability ( $2^{\circ} C$ to $8^{\circ} C$ ) ensures seamless logistical integration into India's Universal Immunization Programme (UIP) and Mission Indradhanush infrastructure.

Preclinical models demonstrated rapid viral clearance in upper and lower airways, proving superior to IM counterparts.
Phase III multicenter trials demonstrated non-inferior systemic immunogenicity to IM Covaxin, alongside significantly higher mucosal IgA and neutralizing antibodies against Omicron variants.
Seroconversion rates exceeded 90%, with heterologous boosters providing a two-fold rise in PRNT50 titers even in low-seroprevalence sites.
Exhibits an excellent safety profile; adverse events are predominantly mild local reactions (rhinorrhea, sneezing in <10% of cases) with no thrombotic, neurological, or anaphylactic signals observed.

Restricts iNCOVACC and iNCOVACC 2.0 use strictly to adults aged 18 years and older.
It is not currently integrated into the UIP or routine pediatric schedules, as national programs have shifted toward adult-focused, optional boosters.

Does not recommend routine pediatric nasal COVID-19 vaccination due to declining disease severity in children.
Supports risk-based boosters for immunocompromised children following individual assessment.
Actively endorses other mucosal platforms, specifically recommending the Nasovac-S live-attenuated influenza vaccine for children over 2 years of age in high-burden seasons.

Major implementation barriers include limited pediatric efficacy data, viral variant evolution, and questions regarding long-term durability requiring booster doses.
Global pediatric trials are actively evaluating next-generation platforms, including replicon-NLC, dNS1-RBD (Phase I trials ongoing for ages 3–17), and formulations utilizing thermostable nano-adjuvants to enhance mucosal penetration.
Future pediatric research focuses on developing multi-valent nasal combinations (COVID-19, influenza, and RSV) to maximize respiratory protection through a single, needle-free delivery system.